Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.
about
Cyclin-dependent kinase inhibitor therapy for hematologic malignanciesThe role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?Targeting Mcl-1 for the therapy of cancerThe quest for an effective and safe personalized cell therapy using epigenetic toolsPhase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma.Combining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies.Rational Combinations of Targeted Agents in AMLPhase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.Bortezomib for the treatment of non-Hodgkin's lymphomaEmerging drug profile: cyclin-dependent kinase inhibitorsA phase I trial of flavopiridol in relapsed multiple myeloma.Gene mutations and actionable genetic lesions in mantle cell lymphoma.Emerging agents for the treatment of mantle cell lymphoma.Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies.Highlights of the Latest Advances in Research on CDK Inhibitors.Romidepsin for the treatment of non-Hodgkin's lymphoma.Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review.Potential Use of Flavopiridol in Treatment of Chronic Diseases.How to manage mantle cell lymphoma.Sangivamycin-like molecule 6 exhibits potent anti-multiple myeloma activity through inhibition of cyclin-dependent kinase-9The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells.Millepachine, a novel chalcone, induces G2/M arrest by inhibiting CDK1 activity and causing apoptosis via ROS-mitochondrial apoptotic pathway in human hepatocarcinoma cells in vitro and in vivo.Managing Tumor Lysis Syndrome in the Era of Novel Cancer TherapiesSynergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response
P2860
Q24561485-701F12CD-E461-4A3D-B94B-16BA8083E043Q26772907-D0BF4822-C999-4AA1-A60B-78DA1F0FB50EQ27011870-D0806110-9D37-453F-A5D3-44820FB1A7C5Q28079389-2A0F9D35-D37C-4FAF-BD64-51871E169312Q33417803-34203A5E-7535-45C9-8100-20AA9D613754Q34114592-38F5C436-24FE-45F3-AA65-2E3B09CD9DC8Q35400933-28488663-636D-4877-8574-574A49B9373AQ35750491-EAD7FFE9-CA08-4B4E-A43D-F4C36D6B177EQ36002546-8C1FB28C-92ED-4574-9A71-CE09DB96DE2DQ36170136-830451B2-3236-439C-8E6A-AFA0E46C20AFQ36868056-CFBD6C1B-DBB6-4A79-A383-0677B02E40A4Q37185372-611E5FA8-D40B-4FCE-B17E-65DBAB17560FQ37624722-6AB06347-8ECF-417D-B392-4A6AC0D9BC0FQ37629080-4219440C-27DF-47AB-A4A1-0218E5F02B3FQ38055498-99CFE51C-7D84-4C4E-AABD-523E80381053Q38122437-3D7EC79F-1D59-4F26-9121-D244AB04C792Q38263222-77673718-3318-4150-B4CF-45C4F38D3C31Q38455740-0BF5FF96-7C6A-451D-8BCB-202EE0DCBA84Q38693748-87A5E203-9EAB-4DFC-A6F0-50C744521084Q38988581-8D2D0F88-E266-46D6-9EAC-3DF767354A5EQ39187610-EA305114-0863-4063-BCE3-E477BB117050Q39281937-F43CF981-FAE3-4962-B0B5-2B19CC4DD063Q46255359-6CB905CC-C29A-453B-97A4-C9AF1C8E5EF5Q54445373-A6601FEF-16F1-43E2-83D9-FA03DB09ED89Q58585587-9E65BD03-747C-4C16-BB60-4EA3CD463454Q58779410-4D90E399-F5D9-47FA-A43B-CDBEA8B46354
P2860
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Phase I trial of bortezomib (P ...... r refractory B-cell neoplasms.
@ast
Phase I trial of bortezomib (P ...... r refractory B-cell neoplasms.
@en
type
label
Phase I trial of bortezomib (P ...... r refractory B-cell neoplasms.
@ast
Phase I trial of bortezomib (P ...... r refractory B-cell neoplasms.
@en
prefLabel
Phase I trial of bortezomib (P ...... r refractory B-cell neoplasms.
@ast
Phase I trial of bortezomib (P ...... r refractory B-cell neoplasms.
@en
P2093
P2860
P1476
Phase I trial of bortezomib (P ...... or refractory B-cell neoplasms
@en
P2093
Austin Doyle
Beata Holkova
Daniel M Sullivan
Domenico Coppola
E Brent Perkins
Ellen Shrader
G David Roodman
Jana Dawson
John D Roberts
P2860
P304
P356
10.1158/1078-0432.CCR-10-2876
P407
P577
2011-03-29T00:00:00Z